HER2+ Breast Cancer

Wolfgang Janni, MD, PhD, University of Ulm, discusses the benefits of HER2-targeted therapies for patients with all stages of HER2-positive breast cancer.

A dual attack on HER2 expression resulted in a 30% objective response rate in heavily pretreated patients with HER2-positive metastatic colorectal cancer.

The irreversible pan-HER tyrosine kinase inhibitor neratinib showed single-agent activity across cohorts of patients with HER2-mutant advanced cancers.

Mark D. Pegram, MD, discusses resistance mechanisms being studied in the quest to overcome resistance to HER2-targeted therapy in breast cancer.

Mohammad Jahanzeb, MD, discusses the SystHERs trial, which was designed to provide real-world insight into current treatment patterns, long-term survival, and patient experience with multiple different treatments for HER2-positive metastatic breast cancer.

C. Kent Osborne, MD, director, Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, discusses the benefits of dual-targeted therapy for patients with HER2-positive breast cancer.

Sara Hurvitz, MD, discusses the amazing evolution in the available treatment options for patients with HER2-positive breast cancer.

Mohammad Jahanzeb, MD, professor of Clinical Medicine, Hematology/Oncology, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, discusses the future of adjuvant treatment in HER2-positive breast cancer.

Debu Tripathy, MD, chair of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses standard and emerging advances in the treatment of patients with HER2-positive breast cancer.

Wolfgang Janni, MD, PhD, University of Ulm, disucusses the management of adverse events in HER2-targeted therapies.

C. Kent Osborne, MD, director, Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, discusses the death of chemotherapy and rise of targeted agents in the treatment of patients with HER2-positive breast cancer.

Debu Tripathy, MD, provided an update on neoadjuvant strategies in HER2-positive breast cancer at the 2017 Miami Breast Cancer Conference.

Michael F. Press, MD, PhD, discusses issues with the ASCO-CAP guidelines on assessment of HER2 amplification by fluorescence in situ hybridization testing.

Sara Hurvitz, MD, Associate Professor of Medicine at UCLA, discusses data supporting the elimination of anthracyclines in HER2-positive breast cancer treatment.

Debu Tripathy, MD, chair of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses neoadjuvant treatment strategies in HER2-positive breast cancer.

Maki Tanioka, MD, PhD, UNC Lineberger Comprehensive Cancer Center, discusses the results of the phase III CALGB 40601 (Alliance) study in HER2-positive breast cancer.

Adding pertuzumab (Perjeta) to trastuzumab (Herceptin) and chemotherapy reduced the risk of recurrence of invasive disease or death in patients with HER2-positive early breast cancer, according to findings from the phase III APHINITY study.